{"paper_id":"7636a004-0f8c-45ea-ab5e-145fa06ece48","body_text":"Abstract\nObjective\nTo observe the clinical efficacy of Quyu Jiedu Recipe (祛瘀解毒方, QJR) in treating endometriosis (EM), and to explore the levels of vascular endothelial growth factor (VEGF) and cell proliferative nucleoprotein antigen (Ki-67), their changes before and after treatment and the clinical significance in the trial.\nMethods\nFifty patients of EM were randomly assigned to two groups. The 26 patients in the QJR group were treated with QJR, and the 24 patients in the gestrinone (GT) group with gestrinone. Besides, a normal control group with 20 healthy women was set up. The therapeutic effects in the two treated groups were compared. Expressions of VEGF and Ki-67 in eutopic endometrium of all subjects (with both patients and healthy women at the median secretive phase) were determined with immunohistochemical stain before treatment, and the determination in the two treated groups was repeated after 3-month treatment in the same phase.\nResults\nBefore treatment, the VEGF and Ki-67 expression positive rates and their mean optic density (MOD) were higher in patients than in healthy women (P<0.05). After treatment, the positive rate and MOD of VEGF expression lowered significantly than before treatment (P<0.05), but those of Ki-67 changed insignificantly, and comparison between the two treated groups showed no significant difference (P>0.05).\nConclusion\nQJR could markedly improve the symptoms of menorrhagia and menstrual disorder, and its mechanism might be related with the lowering of eutopic endometrial VEGF expression. VEGF and Ki-67 show a high expression in eutopic endometrium of patients with EM.\nSimilar content being viewed by others\nReferences\nLang JH. Study and opinion on endometriosis. Chin J Obstet Gynecol 2003; 38(8): 478–480.\nFormulated and issued by Ministry of Health, People’s Republic of China. Guiding principle of clinical research on new drugs of TCM. 1st ed. 1993: 267–271.\nFolkman J, Shing Y. Angiogenesis. Biol Chem 1992; 267: 10931–10934.\nWu MY, Ho HN. The role of cytokines in endometriosis. Am J Reprod Immunol 2002; 9(5): 285–296.\nTan XJ, Lang JH, Liu DY, et al. Expression of vascular endothelial growth factor and thrombospondin-1 mRNA on patients with endometriosis. Fertil Steril 2002; 78(1): 148–153.\nGerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell production. Cancer 1983; 31: 13–20.\nGetdes J, Lemke H, Baisch H, et al. Cell cycle analysis of cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67. Immunol 1984; 133: 1701–1715.\nBaldwin AS. The NF-KB, IKB proteins new discoveries and insights. Annu Rev Immunol 1996; 14: 649–683.\nMay MJ, Ghosh S. IkappaB kinases: kinsmen with different crafts. Science 1999; 284: 271–273.\nOlive DL, Pritts EA. Treatment of endometriosis. N Eng J Med 2001; 345: 266–275.\nLian F, Wang XB, Zhang JW, et al. Thinking and methods of TCM treatment of endometriosis. J Tradit Chin Med 2002; 43(7): 545–546.\nJi ZQ, Gao XX, Song LQ, et al. Experimental study on antiplatelet aggregation in human by 63 kinds of lipid regulating drugs of Chinese Materia Medica. Shandong J Tradit Chin Med 1998; 17: 365–367.\nYe ZY, Ren SG, Li FQ, et al. Effects of paeonol on the microcirculation of rats. Chin J Hemorheol 1999; 9(3): 137–138.\nDictionary of Chinese Materia Medica. Shanghai: Shanghai Scientific and Technical Press, 1986: 478–482, 1093–1097, 1127–1130.\nLiu XJ, Chen WN, Dai G. Study on analgesic action and intolerance of paeonol. Chin Pharmacol Bull 1993; 9(6): 464–467.\nKang BY, Chung SW, Kim SH, et al. Inhibition of interleukin-12 and interferon-gamma production in immune cells by tanshinones from salvia miltiorrhiza. Immunopharmacology 2000; 49: 355–361.\nLi FC, Zhou XL, Mo HL, et al. Experimental study on immunity enhancing effect of Paeonol Injection. Chin J Integr Tradit West Med 1994; 14(1): 37–38.\nLuo ZH. Effect of several kinds of drugs in Chinese material medica on neutrophils in mice. Med J Chin People’s Liberat Army 1994; 19(4): 271.\nZhang YW, Yu Q, Liu P. Minutes of the Fourth National Conference on Obstetrics, Gynecology and Endocrinology. Chin J Obstet Gynecol 2002; 37(5): 263–266.\nShifren JL, Tseng JF, Zaloudek CJ, et al. Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. J Clin Endocrinol Metab 1996; 81(8): 3112–3118.\nMoller B, Rasmussen C, Lindblom B, et al. Expression of the angiogenic growth factor VEGF, FGF-2, EGF and their receptors in normal human endometrium during the menstrual cycle. Mol Hum Reprod 2001; 7(1): 65–72.\nLian F, Liu HP, Wang YX, et al. Study on mechanism of Quyujiedu method in treating endometriosis of stasis-toxic syndrome type. Chin J Integr Tradit West Med 2006; 26(2): 110–113.\nLevitas E, Chamoun D, Udoff LC, et al. Periovulatory and interleukin-1 beta-dependent up-regulation of intraovarian vascular endothelial growth factor (VEGF) in the rat: potential role for VEGF in the promotion of preovulatory angiogenesis and vascular permeability. J Soc Cynecol Investig 2000; 7: 51–60.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nAdditional information\nSupported by Research Projects of Medical Science and Hygiene of Shandong Province 1999 (No. 42)\nRights and permissions\nAbout this article\nCite this article\nLian, F., Liu, Hp., Wang, Yx. et al. Expressions of VEGF and Ki-67 in eutopic endometrium of patients with endometriosis and effect of Quyu Jiedu Recipe (祛瘀解毒方) on VEGF expression. Chin. J Integ. Med. 13, 109–114 (2007). https://doi.org/10.1007/s11655-007-0109-6\nReceived:\nIssue date:\nDOI: https://doi.org/10.1007/s11655-007-0109-6","source_license":"CC0","license_restricted":false}